Content area

|
|

Malignt pleuralt mesoteliom

Forfattere
Sajitha Sophia Sritharan1, 2, Jens Lundby Frandsen2, Øyvind Omland3 & Jens Meldgaard Bruun2 1) Lungemedicinsk Afdeling, Aarhus Universitetshospital 2) Medicinsk Afdeling, Regionshospitalet Randers 3) Det Sundhedsvidenskabelige Fakultet, Klinisk Institut, Arbejdsmedicin, Aalborg Universitetshospital Ugeskr Læger 2018;180:V06170439
Reference: 
Ugeskr Læger 2018;180:V06170439
Sidetal: 
2-6
Malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. The disease is of importance, since the incidence in Denmark is increasing despite cessation of the use of asbestos in the 1980s. MPM has a long latency period, and the first symptom is often dyspnoea, typically caused by pleural effusion. The diagnosis is a challenge, because cytology often is non-conclusive, and thoracoscopy is needed to obtain biopsies for immunohistochemistry. The occupational history is important, since the patients are entitled to compensation. The treatment is often limited to palliation.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Connie Lærkholm Hansen | 17/07
33 kommentarer
af Bente Lützen | 16/07
1 Kommentar
af Christian Frøkjær Thomsen | 16/07
1 Kommentar
af Klaus Roelsgaard | 15/07
2 kommentarer
af Geske Johanne Glahn | 14/07
1 Kommentar
af Finn Redke | 14/07
4 kommentarer
af Finn Redke | 14/07
3 kommentarer